Search results for "COMBINATION"

showing 10 items of 1379 documents

Arterial Destiffening in Previously Untreated Mild Hypertensives After 1 Year of Routine Clinical Management

2016

BACKGROUND Arterial stiffness, measured with pulse wave velocity (PWV), is now classified as a marker of target organ damage (TOD) alongside left ventricular hypertrophy and moderately increased albuminuria. Interventional studies on treated hypertensive patients have shown that PWV could be improved. Our aim was to assess changes in arterial stiffness after 1 year of routine clinical practice in never-treated hypertensive patients. PATIENTS AND METHODS We studied 356 never-treated patients with suspected hypertension. After standard clinical assessment during which presence of TOD was evaluated, hypertension diagnosis was confirmed in 231 subjects who subsequently received standard routine…

AdultMalemedicine.medical_specialtyMean arterial pressureTime FactorsVasodilationPulse Wave Analysis030204 cardiovascular system & hematologyLeft ventricular hypertrophy03 medical and health sciencesVascular Stiffness0302 clinical medicineInternal medicineHeart ratePrevalenceInternal MedicineHumansMedicineArterial Pressure030212 general & internal medicinePulse wave velocityAntihypertensive Agentsbusiness.industryMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeBlood pressureSpainCase-Control StudiesHypertensionAlbuminuriaArterial stiffnessCardiologyDrug Therapy CombinationFemalemedicine.symptombusinessAmerican Journal of Hypertension
researchProduct

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders : Valid predictors of symptomatic response and remiss…

2010

To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome.Biweekly PANSS ratings were performed in 285 inpatients with schizophrenia spectrum disorders within a multicenter trial by the German Research Network on Schizophrenia. Quality of life and subjective well-being were assessed using the Medical Outcomes Study-Short Form 36-Item Health Survey (SF-36), the Subjective Well-being Under Neuroleptic Treatment Scale (SWN-K) and the Adjective Mood Scale (AMS). Response was defined as an initial 20% PANSS total score reduction and remission according to the consensus criteria. Correlation analysis, logistic regression and CART-analysis were performed.I…

AdultMalemedicine.medical_specialtyMedizinLogistic regressionMood scale03 medical and health sciencesYoung Adult0302 clinical medicineQuality of lifeMulticenter trialInternal medicinemedicineHumansSubjective well-beingBiological PsychiatryPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePrognosisAntidepressive Agents3. Good health030227 psychiatryHospitalizationPsychiatry and Mental healthTranquilizing AgentsPsychotic DisordersSchizophreniaCorrelation analysisQuality of LifeSchizophreniaDrug Therapy CombinationFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyAntipsychotic Agents
researchProduct

Aggressive Pharmacological Treatment for Reversing Malignant Bowel Obstruction

2004

Early and intensive pharmacological treatment not only may reduce gastrointestinal symptoms but also reverse malignant bowel obstruction. Fifteen consecutive advanced cancer patients with inoperable bowel obstruction received a combination of drugs including metoclopramide, octreotide, dexamethasone and an initial bolus of amidotrizoato. Recovery of intestinal transit was reported within 1-5 days in fourteen patients, who continued this treatment without presenting symptoms of bowel obstruction until death. This case series establishes that the combination of propulsive and antisecretive agents can act synergistically to allow a fast recovery of bowel transit without inducing unpleasant col…

AdultMalemedicine.medical_specialtyMetoclopramidemedicine.drug_classOctreotideGastroenterologyBolus (medicine)Gastrointestinal AgentsInternal medicineEdemamedicineHumansGeneral NursingDexamethasoneAgedPelvic NeoplasmsTerminal Carebusiness.industrydigestive oral and skin physiologyPalliative CareFecal impactionDrug SynergismRecovery of FunctionMiddle Agedmedicine.diseasedigestive system diseasesBowel obstructionDrug CombinationsAnesthesiology and Pain MedicineTreatment OutcomeAnesthesiaAbdominal NeoplasmsCorticosteroidAntiemeticsFemaleNeurology (clinical)medicine.symptombusinessIntestinal Obstructionmedicine.drug
researchProduct

Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocar…

1994

Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i.v. on days 1, 29; mitomycin C 10 mg/m2 i.v. on day 1. This cycle was repeated every 8 weeks. Out of a total of 34 evaluable patients, 2 (5.8%) had a complete response and 7 (20.6%) had a partial response with an overall median duration of 40 weeks (range 20-128). The median survival of responding patients was not reached after a mean follow-up of 76 weeks, while that of patients with no change and progressive disease was reached at 36 and 13 weeks respectively. Treatment was generally well tolerated with h…

AdultMalemedicine.medical_specialtyMitomycinmedicine.medical_treatmentAdenocarcinomaGastric Adenocarcinoma Chemotherapy Epidoxorubicin Mitomicin CGastroenterologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedEpirubicinAged 80 and overPharmacologyChemotherapybusiness.industryStomachPalliative CareMitomycin CCombination chemotherapyMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracilAdenocarcinomaFemaleFluorouracilbusinessProgressive diseasemedicine.drug
researchProduct

Systemic moxifloxacin vs amoxicillin/metronidazole adjunct to non-surgical treatment in generalized aggressive periodontitis

2014

Background: The objective of this randomized clinical study was to evaluate the effect of systemic administration of moxifloxacin compared to amoxicillin and metronidazole, combined with non-surgical treatment in patients with generalized aggressive periodontitis (GAgP) in a 6-month follow-up. Material and Methods: A total of 39 systemically healthy patients with GAgP were evaluated in this randomized clinical trial. Periodontal parameters were recorded at the baseline during the 1 st , 3 rd and 6 th month. Patients received either 400 mg of moxifloxacin per os once daily or 500 mg of metronidazole and 500 mg amoxicillin per os three times daily for 7 days consecutively. Results: No signifi…

AdultMalemedicine.medical_specialtyMoxifloxacinOdontologíaGastroenterologylaw.inventionYoung AdultPharmacotherapyRandomized controlled trialAnti-Infective AgentslawMoxifloxacinInternal medicineMetronidazoleMedicineAggressive periodontitisHumansAdverse effectGeneral DentistryOral Medicine and Pathologybusiness.industryResearchAmoxicillinAmoxicillin:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryMetronidazoleOtorhinolaryngologyAggressive PeriodontitisUNESCO::CIENCIAS MÉDICASSystemic administrationSurgeryDrug Therapy CombinationFemalebusinessmedicine.drugFluoroquinolonesFollow-Up Studies
researchProduct

Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fl…

2005

The safety and efficacy of early bacterial prophylaxis with piperacillin-tazobactam were prospectively evaluated in 51 autologous peripheral blood stem cell transplantation (PBSCT) recipients. The results were compared with those obtained in 51 control patients receiving oral fluoroquinolones in a retrospective matched-pair control study. Overall, 76% of the study group and 98% of the control group developed at least one febrile episode during neutropenia (P=0.002). Time from neutropenia to the first febrile episode (FFE) was significantly longer in the study group than in the control group (P=0.04). Once a febrile episode appeared, the duration of fever was significantly longer in cases th…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentFevermedicine.drug_classMatched-Pair AnalysisPremedicationAntibioticsPenicillanic AcidBacteremiaGram-Positive BacteriaTazobactamTransplantation AutologousInternal medicineAmphotericin BGram-Negative Bacteriapolycyclic compoundsmedicineHumansAntibacterial agentAgedPiperacillinTransplantationPeripheral Blood Stem Cell TransplantationHematologybusiness.industryHematologyBacterial InfectionsMiddle AgedSurgeryPiperacillin Tazobactam Drug CombinationPiperacillin/tazobactamChemoprophylaxisFemaleStem cellbusinessPiperacillinmedicine.drugFluoroquinolonesBone marrow transplantation
researchProduct

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation

2006

Aims To describe guideline adherence and application of different stroke risk stratification schemes regarding antithrombotic therapy in real-life atrial fibrillation (AF) patients and to assess which factors influence antithrombotic management decisions. Methods and results The Euro Heart Survey enrolled 5333 AF patients in 35 countries, in 2003 and 2004. Prescription of antithrombotic drugs, especially oral anticoagulation (OAC), was hardly tailored to the patient's stroke risk profile as indicated by the joint guidelines of the American College of Cardiology, American Heart Association, and the European Society of Cardiology, ACCP guidelines, or CHADS2 and Framingham risk scores. In mult…

AdultMalemedicine.medical_specialtyOral anticoagulationGuidelineRisk AssessmentElectrocardiographyFibrinolytic AgentsRisk FactorsDrug CombinationAntithromboticmedicineHumansOutpatient clinicRisk factorMultivariate AnalysiStrokeRisk stratificationAgedAntithrombotic therapyFibrinolytic AgentFramingham Risk Scorebusiness.industryRisk FactorAtrial fibrillationMiddle Agedmedicine.diseaseAtrial fibrillationStrokeDrug CombinationsMultivariate AnalysisPractice Guidelines as TopicEmergency medicinePhysical therapyFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessCardioversionsRisk assessmentHumanEuropean Heart Journal
researchProduct

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

2005

Purpose: To verify the experience of the GOIM in the treatment of advanced colorectal cancer patients with the FOLFIRI combination therapy. Patients and methods: Patients entered in three consecutive trials of the GOIM (protocols no. 9706, 9901, and 2301) were reported in this analysis. A total of 287 chemotherapy-naive patients were treated with FOLFIRI regimen: Irinotecan 180mg/m 2 on day 1 with LV5FU2 regimen (LV at 100mg/m 2 administered as a 2-hour infusion before FU at 400mg/m 2 as an intravenous bolus injection, and FU at 600mg/m 2 as a 22-hour infusion immediately after 5FU bolus injection on day 1 and 2); the treatment was repeated every 2 weeks. Results: 287 patients entered in th…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsCombination therapyColorectal cancerLeucovorinGastroenterologyFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsFOLFIRI RegimenHumansMedicineAgedSulfonamidesbusiness.industryCarcinomaLiver NeoplasmsHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanRegimenTreatment OutcomeOncologyCelecoxibFluorouracilFOLFIRIPyrazolesCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

2006

: Background/Aim: Liver steatosis (LS) has been variably associated with chronic hepatitis C (CHC) but whether it affects sustained virological response to antiviral treatment and by what mechanisms is a question still under debate, at least for some genotypes. The aim of this work was to assess the frequency of LS, its relationship with host and viral factors and to what extent it can influence the response to antiviral combination therapy with pegylated interferon (INF)+ribavirin in a group of patients with CHC from a single center. Patients: One hundred and twelve patients with histologically proven CHC were treated with Peg INF-α 2a 180 μg a week subcutaneously for 48 weeks plus ribavir…

AdultMalemedicine.medical_specialtyPathologyAgingCombination therapyGenotypeHepatitis C virusantiviral treatmentHepacivirusInterferon alpha-2Single Centermedicine.disease_causeGastroenterologyAntiviral AgentsSeverity of Illness IndexBody Mass IndexPolyethylene Glycolsliver steatosischemistry.chemical_compoundPegylated interferonInternal medicineGenotypeRibavirinmedicinechronic hepatitis CHumansAspartate AminotransferasesHepatologybusiness.industryRibavirinInterferon-alphaAlanine Transaminasegamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsFatty LiverTreatment OutcomechemistryLiverDrug Therapy CombinationFemaleSteatosisbusinessBody mass indexmedicine.drugLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.

1998

Clozapine is a drug with many side effects, some of them with potentially hazardous outcome (e.g. seizures, agranulocytosis), if not carefully monitored. It has been shown that the metabolism of clozapine may be affected by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs), while there have been reports of improved efficacy on negative symptomatology of clozapine in combination with SSRIs. Therefore, this prospective open clinical trial was performed to investigate the safety and tolerability of the coadministration of clozapine and paroxetine under control of serum concentrations of clozapine and its metabolites and the effect of this combination treatment on psych…

AdultMalemedicine.medical_specialtyPharmacologyPharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyClozapineBiological PsychiatryClozapinePharmacologymedicine.diseaseParoxetineClinical trialPsychiatry and Mental healthParoxetineNeurologyTolerabilitySchizophreniaConcomitantSchizophreniaDrug Therapy CombinationFemaleNeurology (clinical)PsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct